COVID-19: India will also start plasma treatment trial, protocol guideline to be released in two days

COVID-19: India will also start plasma treatment trial, protocol guideline to be released in two days

News

In the treatment of coronavirus, India is now going to start a clinical trial of treatment with antibodies present in the blood of COVID-19 patients who have been cured of plasma treatment. In this episode, the Indian Council of Medical Research will release its protocol guidelines within the next two days. Along with this, approval is also being taken from the Drug Controller General of India.

Advertisement

Senior Scientist of the Indian Council of Medical Research Dr. Manoj Murahekar said that Kerala is currently permitted by the ICMR for the clinical trial of plasma treatment. Also, the state government is also taking approval from the Drug Controller General of India.

The ICMR will soon release a protocol for the clinical trial of this treatment method in the country. Also, approval of DCGI is also being taken. However, under clinical trials, this treatment will be given only to those patients who are on a ventilator.

Advertisement

It is important that plasma treatment is being done in various countries. Under this, the blood of patients recovering from COVID-19 will be given to the plasma patients who have antibodies against this epidemic.

It is important to note that antibodies made under the immunity of the human body are natural medicine, which effectively prevents any infection. Antibodies against any virus or external infection in the body prevent them from joining the cells. The virus multiplies only after it attaches to a cell. So this is a natural and effective way to stop it and the virus is destroyed by not getting home.

The COVID-19 pandemic spread by the Novel Coronavirus is also a form of SARS. In such a situation, it is believed that like SARS, people who are cured of this disease usually have antibodies active for about a year. So the cases of re-infection are very less.

Facebook Comments